Last reviewed · How we verify
Zepzelca
At a glance
| Generic name | Zepzelca |
|---|---|
| Also known as | lurbinectedin |
| Sponsor | Jazz Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Small cell carcinoma of lung
Common side effects
- Leukopenia
- Lymphopenia
- Fatigue
- Anemia
- Neutropenia
- Increased creatinine
- Increased alanine aminotransferase
- Increased glucose
- Thrombocytopenia
- Nausea
- Decreased appetite
- Musculoskeletal pain
Key clinical trials
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC (PHASE1, PHASE2)
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC (PHASE2)
- To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
- Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer (PHASE2)
- Lurbinectedin + Doxorubicin In Leiomyosarcoma (PHASE1, PHASE2)
- Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer (PHASE1)
- Patients With High-grade Pancreatic Neuroendocrine Tumors (PHASE2)
- Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zepzelca CI brief — competitive landscape report
- Zepzelca updates RSS · CI watch RSS
- Jazz Pharmaceuticals portfolio CI